Lokeshwar Soum D, Choksi Ankur U, Smani Shayan, Kong Victoria, Sundaresan Vinaik, Sutherland Ryan, Brito Joseph, Renzulli Joseph F, Sprenkle Preston C, Leapman Michael S
Yale University, School of Medicine, Department of Urology, New Haven, CT.
Yale University, School of Medicine, Department of Urology, New Haven, CT.
Urol Oncol. 2025 May;43(5):336.e13-336.e20. doi: 10.1016/j.urolonc.2024.10.018. Epub 2024 Nov 9.
Comparative studies among biopsy strategies have not been conducted evaluating pathologic concordance at radical prostatectomy(RP), especially with novel micro-ultrasound (micro-US) image-guided biopsy.
A retrospective study among patients with PCa who underwent RP following TRUS, MRI-TRUS fusion, microUS, or MRI-microUS fusion biopsy in a multi-site single institution. We compared GG-upgrade from biopsy to RP based on highest GG in any biopsy core and examined clinical/pathologic factors associated with pathologic upgrading using descriptive statistics, and multivariable logistic-regression analysis.
429 patients between 1/2021 and 6/2023 including 10 (25.6%) who underwent systematic TRUS, 237 (55.2%) MRI-TRUS, 67 (15.6%) MRI-microUS and 15 (3.5%) micoUS-alone biopsy prior to RP. 78 (18.2%) were upgraded on final pathology (TRUS 31 (28.2%), MRI-TRUS 31 (13.1%), MRI-microUS 10 (14.9%), microUS: 6 (40%)) and 99 downgraded. 14 (3.5%) experienced a major upgrade (≥2 GG increase). On multivariable-analysis both MRI-TRUS (odds ratio, OR: 0.31,95% CI:0.17-0.56, P < 0.001) and MRI-microUS (OR: 0.43,95%CI: 0.19-0.98, P = 0.044) were associated with lower odds pathological-upgrade compared with TRUS biopsy alone. No significant differences in the odds of upgrade between TRUS and microUS alone (P > 0.05), or between MRI-microUS and MRI-TRUS(P = 0.696) on pairwise comparisons. MRI-microUS was associated with lower upgrade compared with microUS (OR: 0.26,95% CI:0.08-0.90, P = 0.034). No difference among the biopsy strategies in pathologic downgrading or overall GG concordance. Limitations include retrospective analysis, inter-clinician experience and lesion selection in varying biopsy techniques.
Both MRI-microUS and MRI-TRUS fusion were associated with similarly improved GG concordance compared with TRUS biopsy. No significant differences between microUS-alone and TRUS or between MRI-microUS and MRI-TRUS fusion approaches, may suggest similar accuracy performance for disease sampling.
To our knowledge, this is the first study to investigate GG concordance based on type of biopsy, especially microUS related GG upgrading after RP. In a moderately sized cohort this is the first to investigate pathologic concordance in MRI-microUS fusion compared to MRI-TRUS fusion biopsy. Our study may help urologists in counseling patients after biopsy and choosing the ideal image guided biopsy technique, however randomized controlled trials are needed to validate our results.
We performed a study to see if the type of prostate biopsy, including use of MRI assistance as well as a new image-guided biopsy using a more advanced ultrasound, was better able to identify the aggressiveness of prostate cancer patients had. We found that the new biopsy type when fused with MRI and the existing MRI-guided biopsy type were similar in predicting the type of prostate cancer found at prostate surgery. These were both more accurate than the conventional ultrasound only biopsy.
尚未开展关于活检策略的比较研究,以评估根治性前列腺切除术(RP)时的病理一致性,尤其是新型微超声(micro-US)图像引导活检的情况。
对在多中心单机构接受经直肠超声(TRUS)、磁共振成像-经直肠超声融合(MRI-TRUS)、微超声或磁共振成像-微超声融合活检后行RP的前列腺癌患者进行回顾性研究。我们根据任何活检核心中最高的Gleason分级(GG),比较活检至RP时的GG升级情况,并使用描述性统计和多变量逻辑回归分析,研究与病理升级相关的临床/病理因素。
2021年1月至2023年6月期间的429例患者,其中10例(25.6%)接受了系统性TRUS活检,237例(55.2%)接受了MRI-TRUS活检,67例(15.6%)接受了MRI-微超声活检,15例(3.5%)仅接受了微超声活检,之后进行了RP。78例(18.2%)最终病理升级(TRUS组31例(28.2%),MRI-TRUS组31例(13.1%),MRI-微超声组10例(14.9%),微超声组6例(40%)),99例降级。14例(3.5%)经历了主要升级(GG增加≥2级)。多变量分析显示,与单独的TRUS活检相比,MRI-TRUS(优势比,OR:0.31,95%置信区间:0.17 - 0.56,P < 0.001)和MRI-微超声(OR:0.43,95%置信区间:0.19 - 0.98,P = 0.044)与较低的病理升级几率相关。TRUS与单独的微超声之间(P > 0.05),或MRI-微超声与MRI-TRUS之间(P = 0.696)在升级几率上无显著差异。与微超声相比,MRI-微超声与较低的升级相关(OR:0.26,95%置信区间:0.08 - 0.90,P = 0.034)。活检策略在病理降级或总体GG一致性方面无差异。局限性包括回顾性分析、不同活检技术中医师间经验差异以及病变选择差异。
与TRUS活检相比,MRI-微超声和MRI-TRUS融合均与类似改善的GG一致性相关。单独的微超声与TRUS之间,或MRI-微超声与MRI-TRUS融合方法之间无显著差异,这可能表明在疾病采样方面具有相似的准确性表现。
据我们所知,这是第一项基于活检类型研究GG一致性的研究,尤其是RP后与微超声相关的GG升级情况。在一个中等规模队列中,这是第一项比较MRI-微超声融合与MRI-TRUS融合活检病理一致性的研究。我们的研究可能有助于泌尿外科医生在活检后为患者提供咨询并选择理想的图像引导活检技术,然而需要随机对照试验来验证我们的结果。
我们进行了一项研究,以观察前列腺活检类型,包括使用MRI辅助以及一种使用更先进超声的新型图像引导活检,是否能更好地识别前列腺癌患者癌症的侵袭性。我们发现,与MRI融合的新型活检类型和现有的MRI引导活检类型在预测前列腺手术中发现的前列腺癌类型方面相似。这两种方法都比仅使用传统超声的活检更准确。